Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $2.00 price objective on shares of Aptose Biosciences in a research note on Wednesday, February 12th.

Aptose Biosciences Trading Down 23.2 %

Shares of Aptose Biosciences stock opened at $0.11 on Tuesday. The business’s fifty day moving average price is $0.20 and its 200 day moving average price is $0.30. The stock has a market capitalization of $7.10 million, a P/E ratio of -0.04 and a beta of 0.88. Aptose Biosciences has a twelve month low of $0.11 and a twelve month high of $1.94.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP acquired a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned approximately 4.15% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is currently owned by institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.